Saurabh Lal

Metallurgical Engineering Student., Indian Institute of Technology (BHU), Varanasi
Varanasi, Benaras, India

About Saurabh

Languages

English, Hindi

Areas of Expertise

Metallurgical Engineering, Asset Management, Copywriting & Editing

My TED story

TEDxIITBHU was the experience of a lifetime. When I joined the TEDxIITBHU organizing team, I was given the post of Corporate Communications Analyst which involved bringing in sponsors and roping in speakers. I was then entrusted with the responsibility of building the TEDx brand & culture in the institution. I came up with some innovative publicity ideas which went a long way in achieving the desired goal. This was the point of inspiration, where I envisaged carrying forward the baton of TEDxIITBHU. Other than this, the whole organizing experience involved meeting new people, following deadlines and maintaining high standards. It instilled a renewed sense of work ethics and creativity. I understood the minute details of managing a major event and learnt from the shortcomings as well. In the end, I was truly happy with the effort and the fact that TEDxIITBHU was successful in introducing the TEDx culture in our college.

Comments & conversations

213278
Saurabh Lal
Posted 8 months ago
Make pharmacological companies share research with others.
Whether the prices will skyrocket or not will depend on how common is the disease, is it contagious and can it cause a pandemic. In some cases even the state plays a major role by subsidizing the cost of drugs. Its a valid point and definitely should be part of another conversations.
213278
Saurabh Lal
Posted 8 months ago
Make pharmacological companies share research with others.
I had recently heard this story from a consultant about a case he was working on. There were 2 European pharmaceutical companies ( A & B) in the race for developing a cure for Hepatitis B. Both companies came up with drugs, one with a 2 tablet daily dose and other with a 3 tablet daily dose, having a 70% and 60% efficiency respectively. But together the efficiency would be about 90%. He had to tell company B whether to conduct joint research and improve the efficiency or not. He called this situation an "Ethical Dilemma" as he had to choose between a better cure or a company's profit. But what he surprisingly found out was by the time the process patent by company B ended, they would have perfected their drug to 95% efficiency, given their resources and current research on it. This would make them a monopoly player in the market without compromising on the quality of the cure. So I believe, a common database would pose a similar "Ethical Dilemma" with no certainty of the better option.